To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
The Barbara Ann Karmanos Cancer Institute, cancer centers, and other organizations nationwide recognize July as Sarcoma Awareness Month. Sarcomas are rare tumors that make up about 1% of all adult cancers and 15% of childhood cancers. In 2025, over 13,500 new cases of sarcoma will be diagnosed in the U.S. Karmanos offers an expert team dedicated to diagnosing and treating these uncommon tumors. What is Sarcoma? “Sarcomas are cancers originating in bone or soft tissues, for example, fat, muscle, nerves, ...
Hour Detroit’s 2024 Top Docs List is out; over 50 physicians from the Barbara Ann Karmanos Cancer Institute are listed. Each year, Hour Detroit Magazine puts out an online peer-to-peer review survey conducted by Professional Research Services (PRS) to determine the top physicians in southeastern Michigan. Participating physicians in Livingston, Macomb, Oakland, Washtenaw, and Wayne Counties nominate the best doctors in each field. This year’s list also includes a feature with Elisabeth...
A recently published study led by researchers at the Barbara Ann Karmanos Cancer Institute investigates the molecular mechanism of action of Selinexor in pancreatic ductal adenocarcinoma and the tumor’s surrounding microenvironment. Asfar Azmi, Ph.D., Molecular Therapeutics (MT) Research Program Leader and Pancreas Cancer Research Director at Karmanos, guided this study titled “ Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model ,” publis...